Characterising phenotypically relevant intratumoural heterogeneity in high grade serous ovarian cancer.

被引：0
|
作者：
Fotopoulou, Christina
Cunnea, Paula
Rama, Nona R.
Wulandari, Ratri
Gorgy, Tommy
Gabra, Hani
Stronach, Euan A.
机构：
[1] Univ London Imperial Coll Sci Technol & Med, London, England
[2] Ovarian Canc Act Res Ctr, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e16569
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16569
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Drug resistance in end-stage high-grade serous ovarian cancer.
    Christie, Elizabeth L.
    Alsop, Kathryn
    Au-Yeung, George
    Pandey, Ahwan
    Bowtell, David D. L.
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 17 - 17
  • [22] MOLECULAR AND PHENOTYPIC CHARACTERISATION OF INTRA-TUMOURAL HETEROGENEITY IN HIGH GRADE SEROUS OVARIAN CANCER
    Cunnea, P.
    Curry, E.
    Nixon, K.
    Thol, K.
    Wulandari, R.
    Bowtell, D.
    McNeish, I.
    Fotopoulou, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A50 - A51
  • [23] GENOMIC AND FUNCTIONAL CHARACTERISATION OF INTRA-TUMOURAL HETEROGENEITY IN HIGH GRADE SEROUS OVARIAN CANCER
    Cunnea, Paula
    Curry, Ed
    Christie, Elizabeth
    Nixon, Katherine
    Kwok, Chun Hei
    Ploski, Jennifer
    Wulandari, Ratri
    Bowtell, David
    Fotopoulou, Christina
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A98 - A99
  • [24] Effect of fibroblast heterogeneity on prognosis and drug resistance in high-grade serous ovarian cancer
    Wang, Tingjie
    Tian, Lingxi
    Wei, Bing
    Li, Jun
    Zhang, Cuiyun
    Long, Ruitao
    Zhu, Xiaofei
    Zhang, Yougai
    Wang, Bo
    Tang, Guangbo
    Yang, Jun
    Guo, Yongjun
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [25] Serous ovarian cancer risk factors by grade: Evidence for etiologic heterogeneity
    Poole, Elizabeth M.
    Wentzensen, Nicolas A.
    Trabert, Britton
    Tworoger, Shelley S.
    CANCER RESEARCH, 2016, 76
  • [26] Characterisation of Proteomic heterogeneity following platinum therapy in High-grade Serous Ovarian Cancer
    Wulandari, Ratri
    Nixon, Katherine
    Rama, Nona
    Curry, Ed
    Cunnea, Paula
    Fotopoulou, Christina
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 129 : 40 - 41
  • [27] Variance of HRD score from primary to recurrent in high-grade serous ovarian cancer.
    Chen, Xiaoxiang
    Ni, Jing
    Xu, Xia
    Guo, Wenwen
    Zhao, Qian
    Cheng, Xianzhong
    Zhou, Rui
    Gu, Hongyuan
    Chen, Chen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Prospective analysis of plasma metabolites for early detection of high-grade serous ovarian cancer.
    Sasamoto, Naoko
    Zeleznik, Oana A.
    Vitonis, Allison F.
    Cramer, Daniel W.
    Avila-Pacheco, Julian
    Clish, Clary B.
    Trabert, Britton
    Tworoger, Shelley S.
    Terry, Kathryn L.
    CANCER PREVENTION RESEARCH, 2023, 16 (01)
  • [29] Characterizing chromosome instability in chemonaive, chemosensitive, and chemoresistant high-grade serous ovarian cancer.
    Morden, Claire
    Farrell, Ally
    Sliwowski, Mirka
    Lichtensztejn, Zelda
    Nachtigal, Mark
    McManus, Kirk
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 47 - 48
  • [30] Germline mutations in new susceptibility genes for non-high-grade serous ovarian cancer.
    Pavanello, Marina
    Dicks, Ed
    Song, Honglin
    Ariff, Amir
    Bolithon, Adelyn
    Intermaggio, Maria P.
    Pinese, Mark
    Moysich, Kirsten
    Odunsi, Kunle O.
    Goode, Ellen
    Bowtell, David D.
    Fasching, Peter
    Doherty, Jennifer A.
    Modugno, Francesmary
    Kjaer, Susanne K.
    Webb, Penelope M.
    Wu, Anna
    deFazio, Anna
    James, Paul
    Subramanian, Deepak
    Campbell, Ian
    Gayther, Simon A.
    Pharoah, Paul D. P.
    Ramus, Susan J.
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 98 - 99
12345